Lesson plan
Gedatolisib
Gedatolisib, sold under the brand name Revtorpyk, is an anti-cancer medication used for the treatment of breast cancer. Gedatolisib is a kinase inhibitor. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. Gedatolisib is administered by intravenous infusion. It was developed by Celcuity, Inc. Gedatolisib was approved for medical use in the United States in July 2026.
Article summary
Gedatolisib, sold under the brand name Revtorpyk, is an anti-cancer medication used for the treatment of breast cancer. Gedatolisib is a kinase inhibitor. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. Gedatolisib is administered by intravenous infusion. It was developed by Celcuity, Inc. Gedatolisib was approved for medical use in the United States in July 2026.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.